The genetic-testing company, which collected DNA data from users, is for sale in bankruptcy court. Now, 27 states and the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...

Bankrupt genetic analysis company 23andMe will hold a second auction for its cache of DNA data with an opening bid of $305 ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

The health industry witnesses significant developments as Hims & Hers acquires UK startup Zava, Sanofi plans a $9.5 billion ...

In trying to lead before the system could follow, 23andMe outpaced the very guardrails that might have legitimized it”: A ...

A key decision by the bankruptcy judge could help with protecting consumer data, write Diane Lourdes Dick and Anya Prince.

In a 1 a.m. Eastern time press release, Regeneron said one Phase 3 trial of itepekimab, in adult former smokers with COPD, met the primary target by showing significant reduction of 27% in the sudden ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw its stock touch a 52-week low of $518.68 as the biotech firm contends with ...